There is clear evidence that achieving glycaemic targets reduces the risk of developing complications as a result of type 2 diabetes (T2D). Many patients, however, continue to have suboptimal glycaemic control because of issues that include unclear advice on how to achieve these targets as well as clinical inertia. The two management approaches recommended for patients newly diagnosed with T2D are stepwise and combination therapy, each of which has advantages and disadvantages.
There is clear evidence that achieving glycaemic targets reduces the risk of developing complications as a result of type 2 diabetes (T2D). Many patients, however, continue to have suboptimal glycaemic control because of issues that include unclear advice on how to achieve these targets as well as clinical inertia. The two management approaches recommended for patients newly diagnosed with T2D are stepwise and combination therapy, each of which has advantages and disadvantages.
Stepwise therapy may result in good patient adherence and allow greater individualization of therapy, and minimization of side effects and cost, and so may be appropriate for patients who are closer to goal. Stepwise therapy, however, may also lead to frequent delays in achieving glycaemic goals and longer exposure to hyperglycaemia. Combination therapy, which is now emerging as an important therapy option, has a number of potential advantages over stepwise therapy, including reduction in clinical inertia and earlier and more frequent achievement of glycated haemoglobin goals by targeting multiple pathogenic mechanisms simultaneously, which may more effectively delay disease progression. Compared with stepwise therapy, the disadvantages of combination therapy include reduced patient adherence resulting from complex, multi-drug regimens, difficulty determining the cause of poor efficacy and/or side effects, patient refusal to accept disease, and higher cost. Fixed-dose and fixed-ratio combinations are novel therapeutic approaches which may help address several issues of treatment complexity and patient burden associated with combination therapy comprising individual drugs. The choice of which drugs to administer and the decision to use stepwise vs combination therapy, however, should always be made on an individualized basis.
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β-cell function, combination therapy, glycaemic control, newly diagnosed, stepwise therapy, . 2 To reduce these complications, targeted glycaemic control is recommended. [3] [4] [5] [6] [7] [8] The evidence showing that achievement of glycated haemoglobin (HbA1c) targets reduces the risk of developing complications associated with T2D is robust, with a potential benefit in achieving HbA1c targets as early as possible after diagnosis. [3] [4] [5] [6] [9] [10] [11] The American Diabetes Association (ADA) 12 and the American Association of Clinical Endocrinologists (AACE) 13 have both published recommendations on target HbA1c levels for individuals depending on factors such as age and comorbidities.
Although traditional recommendations have focused on achieving and maintaining HbA1c targets, there is growing interest in tracking glycaemic variation over the course of 24 hours, including fasting and postprandial glucose values, as well as episodes of extreme hypoglycaemia and hyperglycaemia. 14, 15 This additional information may be clinically significant, as minimizing glucose variability through appropriate drug selection could lead to superior, individualized disease management, and provide better quality of life to patients with diabetes 12, [15] [16] [17] ; however, regardless of the parameters used to determine whether adequate glycaemic control is achieved, the use of antidiabetes drugs that also help to halt the progression of the disease should be given priority in the the final decision when combination therapy is implemented. The UK Prospective Diabetes Study (UKPDS) was a landmark study that compared antihyperglycaemic therapies in more than 5000 patients newly diagnosed with T2D over a 20-year period. This study showed that intensive glycaemic control comprising a sulphonylurea, insulin or, in the subset of overweight patients, metformin (to achieve a target fasting glucose level of 6 mmol/L [108 mg/dL]), when compared with conventional therapy (dietary restriction), resulted in significant reductions in rates of retinopathy, neuropathy and nephropathy. 3, 4 A 10-year follow-up study also showed that initial intensive treatment conferred long-term benefits with respect to cardiovascular disease and mortality. 5 In that study, although between-group differences in HbA1c levels were lost after 1 year, a possible legacy of this initial effect may explain the finding that patients treated with sulphonylurea-insulin had a reduced relative risk of any diabetes-related endpoint (9%), microvascular disease (24%), myocardial infarction (15%), and death from any cause (13%), while metformin-treated patients had significant risk reduction in any diabetes-related endpoint (21%), myocardial infarction (33%), and death from any cause (27%). 5 One factor undermining the ability of physicians to help their patients achieve glycaemic targets is the fact that advice varies on the best way of achieving this aim. This is particularly the case for patients with HbA1c levels between 7.5% and 9.0% at diagnosis. Initial monotherapy followed by stepwise addition of add-on medication is recommended for patients with HbA1c <7.5% (AACE) 13 or <9.0%
(ADA). 12 While the ADA recommends starting patients with HbA1c
≥9.0% on dual therapy, the AACE proposes a lower HbA1c threshold of 7.5% for patients to start on this combination therapy approach.
If dual therapy is insufficient to reach the set HbA1c goals, both algorithms recommend stepwise intensification of therapy. These approaches are summarized in Table 1 .
Another factor contributing to the failure of patients with T2D to achieve glycaemic targets is clinical inertia; that is, the failure to establish appropriate targets and to escalate treatment to achieve treatment goals. 20 The In a recent real-world US population study, fewer than 50% of patients with T2D and treatment failure on metformin received intensification within 12 months. 23 Another study revealed that the median time to treatment intensification with additional OADs was 2.9 years in patients with an HbA1c of ≥7.0%, 1.9 years with an HbA1c of ≥7.5%, and 1.6 years with an HbA1c of ≥8.0%. 24 Time to therapy intensification with insulin was >7.1 years for patients receiving 1 OAD, >6.1 years for those receiving 2 OADs, and 6.0 years for those receiving 3 OADs. 24 Clinical inertia is also an issue for patients already on basal insulin, with a median time to treatment intensification from basal insulin initiation of 4.3 years. 21 The benefits of early therapy intensification are supported by a number of studies. In patients newly diagnosed with T2D, early inten- OADs. 26 In another retrospective database analysis, significantly more patients on 1 OAD at baseline (early insulin initiation group) achieved their glycaemic target, compared with patients receiving 2 or ≥3 OADs before insulin initiation; in addition, decrease in HbA1c was significantly greater in patients on 1 OAD at baseline. 27 Recently, however, there has been a move towards more individualized care for patients with T2D to help them better achieve and maintain glycaemic targets. 28, 29 As part of this approach it is important that patients are included in discussions and decisions about their own therapy. 28 According to a survey among US physicians, the major considerations for choosing initial treatments are the patient's overall health, followed by the extent of their HbA1c elevation, and then by their body weight. 30 Ultimately, when choosing any treatment approach for a patient, factors for consideration by healthcare providers should include treatment efficacy, ease of use, tolerability, patient preferences, and adverse events, with the aim of decreasing clinical inertia and improving outcomes. In particular, prescribers should be aware of potential barriers to compliance and medication adherence, such as cost considerations.
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Patient out-of-pocket costs for antidiabetes medications are an important determinant of medication non-adherence and medication underuse, especially in patients with a low income.
31-33
The increasing range of antihyperglycaemic drugs now available may offer potential for greater individualization of therapy. A snapshot of the cellular mechanisms of action and physiological effects of the most commonly prescribed antihyperglycaemic drugs is provided in Table 2 , 2 showing that these drugs provide the potential to address multiple pathophysiological defects. Newer drugs (e.g. glucagon-like peptide-1 receptor agonists [GLP-1RAs]) have multiple mechanisms of action 34 while others (e.g. sodium-glucose co-transporter-2
[SGLT2] inhibitors) are associated with novel mechanisms of action. 35 In addition, a number of studies have shown potential beneficial effects of antihyperglycaemic drugs on the preservation of β-cell function and mass, including incretin-based therapies (e.g. GLP-1RAs, dipeptidyl peptidase-4 [DPP-4] inhibitors), as well as thiazolidinediones (TZDs). [36] [37] [38] [39] [40] Moreover, even insulin glargine is associated with both direct and indirect evidence of β-cell preservation. 41, 42 The aim of the present review was to explore the advantages and disadvantages of stepwise and combination therapy approaches in the management of patients newly diagnosed with T2D, in order to help physicians determine which therapy approach provides the best means of individualizing therapy.
| STEPWISE THERAPY
Historically, stepwise treatment intensification in patients with T2D
has been the most common approach to glycaemic control. Patients are usually initiated on metformin alone, or, if tolerated and not contraindicated, another oral agent (such as sulphonylurea/glinide, pioglitazone, a DPP-4 inhibitor, or an SGLT2 inhibitor), a GLP-1RA, or basal insulin. 2, 43 Therapy intensification is then recommended if monotherapy does not achieve or maintain an HbA1c target over 3 months. 43 ADA guidelines, despite generally recommending initial monotherapy, recommend initial dual therapy with two non-insulin agents or with insulin itself for patients with baseline HbA1c levels ≥9.0%. 2, 43, 44 For patients with HbA1c ≥10.0%, blood glucose ≥300 mg/dL, or with symptoms of hyperglycaemia, combination injectable insulin therapy (basal insulin, plus either a single injection of rapid-acting insulin before the largest meal, a GLP-1RA, or changing to premixed insulin twice daily) is recommended. 43 With this approach, additional treatments are sequentially added when previous treatments lose their effectiveness and patients become hyperglycaemic. 43 Insulin in particular is seen as a last resort, and is only added to treatment when all other therapies have failed. 45 More recently, however, there has been a move towards more individualized care for patients to help them achieve and maintain glycaemic targets early in the course of the disease. 28, 29 Thus, it is important to consider whether the traditional stepwise therapy actually provides an appropriate means of individualizing therapy for maximum benefits in a given patient.
| Advantages
Potential advantages of stepwise therapy include good patient adherence, individualization of therapy, and minimization of side effects and cost; therefore, this approach may be appropriate for patients who are closer to goal. Stepwise treatment, if implemented correctly in a timely manner and combined with lifestyle modification, can result in large proportions of patients maintaining acceptable longterm HbA1c levels similar to those seen with combination therapy. 4, 46, 47 A stepwise approach also allows the efficacy and safety of each drug in specific patients to be assessed in isolation, allowing greater individualization of care. The likelihood of side effects is lower with sequential addition of single drugs, compared with multiple drugs added at the same time, and if side effects do occur, it is easier to identify the causative drug if only one drug is added at a time. 44, 48 As patients are more likely to stop treatment or skip doses as regimens increase in complexity, stepwise treatment with just a single agent added at a time allows patients to become comfortable and confident with each component of their treatment before the next one is added, with the potential for greater treatment adherence. 49 Cost, another potential factor reducing adherence, 49 is generally lower with a single medication than with multiple medications.
| Disadvantages
Potential disadvantages of stepwise therapy include delays in achiev- 
| COMBINATION THERAPY
The novel idea of combination therapy (defined here as treatment with ≥2 oral agents or injectables) early in T2D is based on the rationale that multiple defects contribute to the development of chronic hyperglycaemia and its complications. This has been extensively ; these defects are summarized in Table 3 . Because of the multifactorial nature of glucose intolerance, it was proposed that multiple drugs, targeting the different pathophysiological defects, should be used together, with the aim of reversing these abnormalities, in addition to reducing HbA1c. 52 events. [53] [54] [55] In addition to the already described range of antihyperglycaemic drugs (Table 2) , other approaches for combination therapy include the use of fixed-dose combination (FDC) drugs, with several of these combinations being approved for treatment of T2D in recent years. 56 Lastly, new approaches, such as titratable, fixed-ratio combinations (FRCs) of basal insulin plus GLP-1RAs, offer the multimechanistic actions of an incretin while also addressing the insulin deficiency common to many patients with T2D. [57] [58] [59] [60] In practice, our recommendation is the introduction of multiple drugs to be implemented at the start, say within 3 to 6 months of the initial diagnosis, resulted in significant improvements in HbA1c and increases in attainment of glycaemic goals (HbA1c <7.0%) compared with metformin monotherapy. 67 Another meta-analysis of RCTs comparing intial combination therapy with DPP-4 plus metformin and metformin monotherapy showed similar benefits with regard to improved glycaemic control. 68 Research comparing initial combination therapy (with metformin, pioglitazone and exenatide) with stepwise therapy (with sequential metformin, glipizide, and basal insulin glargine) suggested both shortand long-term glycaemic benefits for early combination therapy. 46 Patients receiving combination therapy had greater short-term HbA1c reductions than those receiving stepwise therapy; after 6 months, HbA1c was 6.0% with combination therapy vs 6.2% with stepwise therapy (0.2% difference, P = .03). In the longer term, the difference between the two treatment groups increased over time, reaching 0.55% after 24 months (P < .0001). 46 A number of studies have demonstrated some benefit of early combination therapy in β-cell function preservation, although these studies did not provide a comparison with a stepwise approach. For example, the COSMETIC study, which investigated early initial combination therapy with the DPP-4 inhibitor sitagliptin plus metformin, showed improvements in β-cell function, 69 and a study of combination therapy with the DPP-4 inhibitor alogliptin and the TZD pioglitazone showed improvements in β-cell function in trials ranging from 12 to 52 weeks. 70 Another recent study demonstrated that in newly diagnosed patients with T2D who received early combination therapy with either insulin plus metformin or triple oral therapy with metformin, glyburide, and pioglitazone, β-cell function was maintained for 6 years in both groups. 71 The VERIFY (Vildagliptin Efficacy in combination with metfoRmIn into whether early combination treatment may slow β-cell deterioration and provide long-term clinical benefits to patients, and indicate whether this approach is superior to a stepwise approach. 72 The benefits of combination therapy may be attributable to both glycaemic and non-glycaemic factors, such as the reduction of blood pressure and lipids with GLP-1RAs and the reduction of blood pressure with SGLT2 inhibitors (Table 2) . >7.5% on the intial dual therapy, basal insulin will be added to the three non-insulin groups (for triple therapy), to compare outcomes between the 4 groups in a tertiary endpoint.
Results from this trial may help provide a better assessment of drug cost-effectiveness and additional guidance to clinicians. 7 
| Disadvantages
Compared with stepwise therapy, the disadvantages of combination therapy include reduced patient adherence to complex, multi-drug regimens, difficulty determining the cause of poor efficacy and/or side effects, patient refusal to accept disease (denial), and higher costs. 44, 73, 74 Patient adherence decreases as therapy complexity and the number of medications increases. 49 This may be a particular issue for Another potential disadvantage of combination therapy is that it may be difficult to determine which of the drugs is responsible for the efficacy (or lack of efficacy) -or side effects -associated with the combination regimen in individual patients. 48 Combination therapy is initially more costly than therapy with a single agent in stepwise therapy, although if superior glycaemic control is achieved over time the avoidance of complications is likely to offset the initial higher medication cost. 26 
| Fixed-dose combinations
Many glucose-lowering agents are now available as single-pill combinations or FDCs for oral combination therapy. These include formulations of metformin with DPP-4 and SGLT2 inhibitors, and non-metformin FDCs, such as combinations of a DDP-4 with a SGLT2 or TZD. 56, 75 FDCs may provide several advantages that make them a good option for use in combination therapy; these include reducing the complexity of the dosing regimen, and improving patient adherence by reducing pill burden and dosing frequency. 75 As FDCs are also available in a number of dosage combinations, they still provide physicians with options for dose adjustments and titration. 56 Retrospective database analyses, systematic literature reviews, and meta-analyses suggest that patient adherence was significantly better in patients with T2D receiving an FDC than in those receiving the same combination as separate pills. 76, 77 In particular, these studies indicate that, while adherence slightly decreases when switching from monotherapy to combination therapy, the decrease is smaller when patients switch to an FDC compared with coadministered therapy. Similarly, when patients on dual therapy switch to an FDC of the same medication, adherence increases compared with remaining on co-administered therapy. 76 An FDC of rosiglitazone and glimepiride, for example, was shown to increase adherence compared with a dual therapy regimen where the drugs were taken separately. 78 Data from a physician-interview study indicate that the decision to prescribe an FDC is often motivated by the perception that FDCs increase patients' compliance, and that FDCs are associated with improved treatment satisfaction among patients. 79 In addition to the benefit of simplifying the treatment regimen, FDCs combining 2 agents at lower doses may also provide improved tolerability and greater efficacy compared with high-or maximal-dose monotherapy, 75, 80 or co-administered combination therapy. 77 Collectively, this may help prescribers to overcome clinical inertia, particularly in patients who are more likely to experience delays in their treatment intensification, such as patients who are less able to adhere to complex treatment regimens (i.e. the elderly, mentally or physically impaired patients, or those with irregular work schedules). The study showed that, in addition to improving adherence, FDC therapy was a cost-effective approach compared with loose-dose combination therapy in terms of total predicted monthly all-cause costs ($1008 vs $1053; P = .006) and T2D-related costs ($142 vs $155; P < .001). 83 After adjusting for clinically meaningful demographic and clinical variables, there was no statistically significant difference in efficacy outcomes (hypoglycaemia) between groups in this study (odds ratio of hypoglycaemic event occurrence 0.8; P = .213). 83 Despite the potential advantages in improving patient adherence and reducing costs, the use of FDCs in clinical practice has been relatively limited. In 2012, only 6.7% of non-insulin antidiabetes drug prescriptions were for combination products, predominantly combinations of metformin with either sitagliptin or glyburide. cells. In addition, they have been shown to inhibit gastric acid secretion and gastric emptying, and to increase satiety. 34, 89 Several advantages may be offered by FRCs for combination therapy, although, given their current labels, not in treatment-naive patients. [85] [86] [87] [88] These include the potential to improve adherence to medication by simplifying regimen complexity 90 via reduction of the number of daily injections needed. [57] [58] [59] [60] Further, the use of an insulin/GLP-1RA FRC appears to mitigate the side effects of its individual components, leading to better tolerability and, consequently, lower rates of discontinuation, thus potentially helping increase medication adherence. 91 In clinical trials, both weight gain and the incidence of hypoglycaemia were found to be lower (or at least not increased)
with the FRC than with basal insulin, despite improved glycaemic control and greater reductions in HbA1c levels. [57] [58] [59] [60] 92 In addition, the incidence of gastrointestinal adverse events was lower with FRCs compared with GLP-1 RAs alone. [57] [58] [59] [60] The burden of treatment cost for patients is an important factor to consider in treatment decisions; 2,13,43 however, current pricing information for available FRCs indicates that their cost is lower than the sum of their two components, and similar to the price of GLP-1RA therapies alone. 93 In with sulphonylureas but with the disadvantage that the disease will continue to progress. There is also a greater risk of hypoglycaemia and/or weight gain, in view of the overlapping effects of exogenous and endogenous insulin secretion. Another factor that may impact treatment decisions is benefit beyond glycaemic control. As the impact of T2D on cardiovascular outomes remains substantial, 96 physicians may prioritize medication based on outcomes that include cardiovascular risk reduction. Recent reviews of the available data suggest that empagliflozin, liraglutide, and semaglutide, in particular, confer cardiovascular benefit in addition to clinically useful glucoselowering effects in patients specifically with long-standing, suboptimally controlled T2D and established atherosclerotic cardiovascular disease. 97, 98 Pioglitazone has also been associated with a reduced risk of major adverse cardiovascular events (composite of non-fatal myocardial infarction, non-fatal stroke and cardiovascular death) in patients with insulin resistance, prediabetes and T2D, but with an increased risk of heart failure, bone fracture, oedema, and weight gain. 99 Overall, these findings further support the individualization of therapy, with an expansion of the treatment algorithms from those based primarily on HbA1c values to include cardiovascular disease outcomes. Further research is required to elucidate the mechanisms by which these agents exert their cardiovascular benefit; evidence suggests that it is not through their antihyperglycaemic effects 97 
| SUMMARY AND CONCLUSIONS
Type 2 diabetes is a major global contributor to disability and premature death. To decrease both short-and long-term microvascular and macrovascular complications, it is important to help patients reach their glycaemic targets through optimization of treatment. Contributing to the problem of many patients failing to achieve their glycaemic targets is the confusion attributable to diabetes treatment algorithms from different clinical associations proposing different means of achieving glycaemic targets, particularly for patients with HbA1c levels between 7.5% and 9.0% at diagnosis. 100 Stepwise treatment has potential advantages with regard to adherence, individualization of therapy, cost, and minimization of side effects, and as such is perceived by many to be appropriate for patients who are closer to goal. The disadvantage of this approach is that it may result in delays in achieving glycaemic goals, leading to longer durations where patients are exposed to hyperglycaemia, and the associated potential for increased risk of microvascular and macrovascular complications.
Advantages of combination therapy include earlier and greater reductions in HbA1c, and potentially greater preservation and restoration of β-cell function. It should be noted though, that, in the absence of studies directly comparing the same agents used as either initial combination or stepwise therapy, it is possible that the benefits observed with regard to preservation of β-cell function and durability of glycaemic control may be attributable to the agents used and their specific mechanisms of actions, rather than the timing of administration. 100 In addition, there is evidence of benefits in non-glycaemic outcomes, such as improvement in some cardiovascular risk factors (for canagliflozin, empagliflozin, and liraglutide), that may also support the use of multiple drugs in an early combination therapy strategy.
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Drawbacks of this approach include reduced patient adherence with complex, multi-drug regimens, difficulty determining the cause of poor efficacy and/or side effects, and higher costs. Adherence issues, however, may be addressed by the use of FDCs and FRCs to reduce therapy complexity and patient burden.
In conclusion, there are advantages and disadvantages to both a stepwise and a combination therapy approach in the management of patients newly diagnosed with T2D (Table 4 ).
The current lack of real-world studies comparing stepwise vs initial combination therapy does not allow appraisal of the practical considerations regarding advantages and disadvantages of both approaches. Individualization of therapy currently relies on results from RCTs, which present some limitations, thus potentially limiting the generalization of their findings. These include, for example, strict inclusion/exclusion criteria, focus of selected populations, short duration, lack of power to assess subpopulations prospectively, and the relatively artificial environments in which they are conducted. 104 While there are no long-term head-to-head studies currently available comparing stepwise and combination therapy, from the point of view of a healthcare provider, factors to consider when making individualized treatment decisions should include not only treatment efficacy and maintenance of glycaemic control with minimal daily variability, while avoiding hypoglycaemia, but also the effective halting of disease progression. Moreover, adverse effects, acceptability, tolerability, patient quality of life, preferences, medication burden, and costs, as well as treatment complexity, should be taken into consideration in the selection of individual drugs, as well as in the decision to use stepwise vs combination therapy.
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